ReviewVaccines2021
Current State of the First COVID-19 Vaccines.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double Blind, Controlled, Phase III Clinical Trial (Immunobridging Study) of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) in Healthy Population Aged 18 Years and Above
An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
Who cites it
44 citing papers in PubMed.
- COVID-19 Vaccine Passport and International Traveling: The Combined Effect of Two Nudges on Americans' Support for the Pass.International journal of environmental research and public health · 2021Trial
- Delay, Doubt and Dollars: Exploring Delay and Probability Discounting of Free and Paid HIV Vaccines among Sexual and Gender Minorities.AIDS and behavior · 2026Article
- Investigating Parental Perception and Intentions Toward COVID-19 Vaccination for Children in Ras Al Khaimah.Health science reports · 2026Article
- Comparison of Immune Cell Transfection by Different Vaccine Vectors After Intradermal Injection.Vaccines · 2026Article
- Adverse events associated with AstraZeneca COVID-19 vaccine among adults in Greater Kampala, Uganda: a cross-sectional study.African health sciences · 2024Article
- Manifestations of adverse events post Sinovac vaccine immunization at Wirasakti Hospital, Kupang.Journal of public health in Africa · 2023Article
- A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia.Vaccines · 2023Review
- Determinants of COVID-19 cases and deaths in OECD countries.Zeitschrift fur Gesundheitswissenschaften = Journal of public health · 2023Article
- COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.BioMed research international · 2023Review
- Efficacy and Short-Term Safety of COVID-19 Vaccines: A Cross-Sectional Study on Vaccinated People in the UAE.Vaccines · 2022Article
- Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.Vaccines · 2022Review
- Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.Journal of drug delivery science and technology · 2022Review
- Comparison of replicating and nonreplicating vaccines against SARS-CoV-2.Science advances · 2022Article
- A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Generalized Susceptible-Exposed-Infectious-Recovered model and its contributing factors for analysing the death and recovery rates of the COVID-19 pandemic.Applied soft computing · 2022Article
- Prevalence of and Factors Associated With Post-Coronavirus Disease 2019 (COVID-19) Condition in the 12 Months After the Diagnosis of COVID-19 in Adults Followed in General Practices in Germany.Open forum infectious diseases · 2022Article
- Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm.Acta pharmaceutica Sinica. B · 2022Article
- Article
- Global interest in vaccines during the COVID-19 pandemic: Evidence from Google Trends.Vaccine: X · 2022Article
- SARS-CoV-2 vaccine-associated-tinnitus: A review.Annals of medicine and surgery (2012) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.